Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIGURE 1.
FIGURE 1.

Chemical structures of compounds used in this study. SSA (1), spliceostatin A; PB (2), pladienolide B; HB (3), herboxidiene; iSSA (4), inactive spliceostatin A (also known as SSE, spliceostatin E); iPB (5), inactive pladienolide B; iHB (6), inactive herboxidiene. IC50 refers to the concentration required to reduce in vitro splicing by half compared to DMSO-treated control reactions. Inactive compounds do not interfere with in vitro splicing up to a concentration of 200 µM.

This Article

  1. Published in Advance January 7, 2016, doi: 10.1261/rna.053108.115 RNA 22: 350-359

Current Issue

  1. August 2026, 32 (8)
  1. Current Issue
  1. Alert me to new issues of RNA